New treatment approved for wet age-related macular degeneration

Novartis announced on October 8, 2019 that the US Food and Drug Administration (FDA) approved BEOVU® (brolucizumab-dbll) injection for the treatment of wet age-related macular degeneration (wet AMD). This is the fourth anti-VEGF drug treatment to be approved for wet AMD, the others being Lucentis (Genentech), Eylea (Regeneron), and off-label Avastin (Genentech). Similar to its predecessors, BEOVU® carries a recommended dosing schedule of monthly for the first three doses followed by one dose every 8-12 weeks. This approval now provides more options for doctors and patients.

SOURCE: Novartis press release

For descriptions of this and other anti-VEGF treatments for wet AMD now in clinical use and in trials, see Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration